Another radiation restenosis treatment tested :
This article was originally published in Clinica
Executive Summary
Theragenics, a US company that makes the Theraseed prostate brachytherapy device, is to test its palladium-103 technology on animal models of coronary restenosis. The Buford, Georgia-based company has signed an agreement with the Atlanta Cardiovascular Research Institute to conduct a two-phase animal study, due to begin next month. The first phase will aim to determine whether a catheter-based Pd-103 source can inhibit restenosis, while the second will test stent-based Pd-103 devices. Theragenics is the latest in a long line of companies trying to exploit the anti-restenotic properties of various types of radiation sources.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.